作者
Li-Fang Chen,Yuan-Yuan Chen,Fei-Tian Min,Weibo Wen,Sufeng Luo,Ya Luo,Qin-Rong Li,Zi-Qing Xu,Shasha Liu,Xia Chen,Ning Wang,Huantian Cui,Xiao-Rong Wang
摘要
BACKGROUND Ya-Han-Lu-Duan (YHLD) decoction is a classical Dai ethnic prescription widely used to treat intestinal inflammatory diseases. However, its ability to prevent colitis-associated colorectal cancer (CAC), the molecular mechanisms responsible, and the active constituents of the formulation remain unknown. AIM To elucidate YHLD’s therapeutic mechanisms against CAC, focusing on tumor microenvironment (TME). METHODS We evaluated YHLD in a mouse model of CAC induced by azoxymethane and dextran sulfate sodium. To elucidate mechanisms, we applied transcriptomic and untargeted metabolomic analyses to colon tissues from treated and control animals. Key pathways identified by these omics approaches were validated by enzyme-linked immunosorbent assay, western blot, and immunofluorescence. We characterized YHLD’s chemical constituents using UPLC-Q-TOF-MS, then performed molecular docking to model interactions between major components and enzymes in arachidonic acid (AA) metabolism, providing a preliminary screen for potential molecular targets. RESULTS YHLD significantly attenuated body weight loss and colon shortening in CAC mice, alleviated colonic histopathological injury, and reduced tumor formation. Transcriptomic analysis showed that genes differentially expressed after YHLD treatment were enriched in TME-related pathways, including Cytokine-cytokine receptor interaction and extracellular matrix-receptor interaction. YHLD decreased the expression of pro-inflammatory and pro-tumor growth factors and reduced markers of cancer-associated fibroblasts and myeloid-derived suppressor cells. Untargeted metabolomic analysis further identified AA metabolism as a pathway co-enriched in both transcriptomic and metabolomic datasets. Consistently, YHLD suppressed the expression of key AA metabolism enzymes, PTGS2 and ALOX12. In addition, major components of YHLD, including Pentahydroxybufostane, Clematoside B, Psammosilenin A and Dulcoside A, showed high binding affinity to PTGS2 and ALOX12, respectively, suggesting that YHLD may coordinately regulate AA metabolism through multiple active components. CONCLUSION This study provides the first evidence that YHLD exerts a significant protective effect against CAC. The underlying mechanism likely involves inhibition of ALOX12-mediated and PTGS2-mediated AA metabolism, suppression of cancer-associated fibroblast activation and myeloid-derived suppressor cells infiltration, and remodeling of the immunosuppressive TME, thereby alleviating CAC progression. These findings offer experimental and mechanistic support for the development of YHLD as a preventive agent for CAC.